Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Magazine

A Boost For France's Sanofi-Aventis


The French government's goal of creating a national pharmaceutical champion got a big boost on Nov. 9 when Paris-based Sanofi-Aventis released promising data on an experimental drug that helps people lose weight and stop smoking. Hailed as a breakthrough in the treatment of obesity, Acomplia blocks the same biological trigger in the brain that gives cannabis smokers the munchies. Data from a two-year trial showed that patients taking Acomplia lost nearly four times as much weight as participants given sugar pills. Analysts expect Acomplia, which will likely be filed for approval in the U.S. and Europe by mid-2005, to be the new company's first blockbuster. Sanofi and Aventis merged earlier this year under French government pressure.

EDITED BY Edited by Rose Brady


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus